Key clinical point: Patients with rheumatoid arthritis (RA) were at an increased risk for lung cancer compared with the general population, with seropositivity being a strong and independent risk factor above what can be explained by smoking.

Major finding: Patients with RA vs. general population were at increased risk for lung cancer (adjusted hazard ratio [aHR] 1.70; 95% CI 1.54-1.87), with the risk being even higher among ever smokers (aHR 1.82; 95% CI 1.06-3.17) or current smokers (aHR 2.73; 95% CI 1.21-6.16) and double seropositivity being a strong and independent risk factor (aHR 6.21; 95% CI 1.47-26.33).

Study details: This was a population-based matched cohort study including 44,101 patients with RA who were individually matched with 216,495 control individuals from the general population and prospectively followed for the occurrence of lung cancer.

Disclosures: This study was funded by the Swedish Research Council and other sources. K Chatzidionysiou declared receiving consulting fees from various sources. J Askling declared serving as principal investigator and having ties with various sources.

Source: Chatzidionysiou K et al. Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking. RMD Open. 2022;8(2):e002465 (Oct 21). Doi: 10.1136/rmdopen-2022-002465

Key clinical point: Patients with rheumatoid arthritis (RA) were at an increased risk for lung cancer compared with the general population, with seropositivity being a strong and independent risk factor above what can be explained by smoking.

Major finding: Patients with RA vs. general population were at increased risk for lung cancer (adjusted hazard ratio [aHR] 1.70; 95% CI 1.54-1.87), with the risk being even higher among ever smokers (aHR 1.82; 95% CI 1.06-3.17) or current smokers (aHR 2.73; 95% CI 1.21-6.16) and double seropositivity being a strong and independent risk factor (aHR 6.21; 95% CI 1.47-26.33).

Study details: This was a population-based matched cohort study including 44,101 patients with RA who were individually matched with 216,495 control individuals from the general population and prospectively followed for the occurrence of lung cancer.

Disclosures: This study was funded by the Swedish Research Council and other sources. K Chatzidionysiou declared receiving consulting fees from various sources. J Askling declared serving as principal investigator and having ties with various sources.

Source: Chatzidionysiou K et al. Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking. RMD Open. 2022;8(2):e002465 (Oct 21). Doi: 10.1136/rmdopen-2022-002465

Key clinical point: Patients with rheumatoid arthritis (RA) were at an increased risk for lung cancer compared with the general population, with seropositivity being a strong and independent risk factor above what can be explained by smoking.

Major finding: Patients with RA vs. general population were at increased risk for lung cancer (adjusted hazard ratio [aHR] 1.70; 95% CI 1.54-1.87), with the risk being even higher among ever smokers (aHR 1.82; 95% CI 1.06-3.17) or current smokers (aHR 2.73; 95% CI 1.21-6.16) and double seropositivity being a strong and independent risk factor (aHR 6.21; 95% CI 1.47-26.33).

Study details: This was a population-based matched cohort study including 44,101 patients with RA who were individually matched with 216,495 control individuals from the general population and prospectively followed for the occurrence of lung cancer.

Disclosures: This study was funded by the Swedish Research Council and other sources. K Chatzidionysiou declared receiving consulting fees from various sources. J Askling declared serving as principal investigator and having ties with various sources.

Source: Chatzidionysiou K et al. Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking. RMD Open. 2022;8(2):e002465 (Oct 21). Doi: 10.1136/rmdopen-2022-002465

Key clinical point: Tocilizumab was more effective than etanercept in inhibiting the radiographic progression of joint erosion in rheumatoid arthritis (RA), with joint damage progression being significantly associated with the baseline clinical disease activity index (CDAI) score.

Major finding: At 12 months, a significantly higher proportion of patients showed no radiographic progression of joint erosion with tocilizumab vs etanercept (change in total Sharp/van der Heijde score [erosion] ≤0%; 86.8% vs 63.2%; P = .032). The progression of radiographic joint erosion was significantly correlated with the baseline CDAI score (odds ratio 1.05; P = .037).

Study details: This was a retrospective cohort study including 187 patients with RA who received tocilizumab or etanercept for at least 12 months.

Disclosures: This study did not report the source of funding. The authors declared no conflict of interests.

Source: Hayashi S et al. Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment. Sci Rep. 2022;12(1):17524 (Oct 20). Doi: 10.1038/s41598-022-22152-w

Key clinical point: Tocilizumab was more effective than etanercept in inhibiting the radiographic progression of joint erosion in rheumatoid arthritis (RA), with joint damage progression being significantly associated with the baseline clinical disease activity index (CDAI) score.

Major finding: At 12 months, a significantly higher proportion of patients showed no radiographic progression of joint erosion with tocilizumab vs etanercept (change in total Sharp/van der Heijde score [erosion] ≤0%; 86.8% vs 63.2%; P = .032). The progression of radiographic joint erosion was significantly correlated with the baseline CDAI score (odds ratio 1.05; P = .037).

Study details: This was a retrospective cohort study including 187 patients with RA who received tocilizumab or etanercept for at least 12 months.

Disclosures: This study did not report the source of funding. The authors declared no conflict of interests.

Source: Hayashi S et al. Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment. Sci Rep. 2022;12(1):17524 (Oct 20). Doi: 10.1038/s41598-022-22152-w

Key clinical point: Tocilizumab was more effective than etanercept in inhibiting the radiographic progression of joint erosion in rheumatoid arthritis (RA), with joint damage progression being significantly associated with the baseline clinical disease activity index (CDAI) score.

Major finding: At 12 months, a significantly higher proportion of patients showed no radiographic progression of joint erosion with tocilizumab vs etanercept (change in total Sharp/van der Heijde score [erosion] ≤0%; 86.8% vs 63.2%; P = .032). The progression of radiographic joint erosion was significantly correlated with the baseline CDAI score (odds ratio 1.05; P = .037).

Study details: This was a retrospective cohort study including 187 patients with RA who received tocilizumab or etanercept for at least 12 months.

Disclosures: This study did not report the source of funding. The authors declared no conflict of interests.

Source: Hayashi S et al. Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment. Sci Rep. 2022;12(1):17524 (Oct 20). Doi: 10.1038/s41598-022-22152-w

Key clinical point: Significant proportion of patients with high-risk early rheumatoid arthritis (RA) achieved the treatment target with a combination of methotrexate and step-down prednisolone, whereas nonresponders benefited from treatment intensification albeit with more adverse events.

Major finding: Overall, 73% of patients at high risk achieved the treatment target at 13 weeks. A significant proportion of nonresponders who were at high risk achieved the treatment target with treatment intensification vs continuation (80% vs 44%; difference 36%; P = .04), but experienced more adverse events (P < .01).

Study details: This study included 190 patients with early RA from the COBRA treat-to-target trial, of which high-risk patients received prednisolone (30 mg/day tapered to 7.5 mg/day) and methotrexate (increased from 10 to 25 mg/week). At 13 weeks, nonresponders were randomly assigned to treatment continuation or intensification (methotrexate 25 mg/week; prednisolone 60 mg/day tapered to 7.5 mg/day; sulfasalazine 2 g/day; and hydroxychloroquine 400 mg/day).

Disclosures: This study was supported by an unrestricted grant from Pfizer. M Boers and WF Lems reported ties with various sources.

Source: Hartman L et al. Favorable effect of a ‘second hit’ after 13 weeks in early RA non-responders: The Amsterdam COBRA treat-to-target randomized trial. Rheumatology (Oxford). 2022 (Oct 7). Doi: 10.1093/rheumatology/keac582

Key clinical point: Significant proportion of patients with high-risk early rheumatoid arthritis (RA) achieved the treatment target with a combination of methotrexate and step-down prednisolone, whereas nonresponders benefited from treatment intensification albeit with more adverse events.

Major finding: Overall, 73% of patients at high risk achieved the treatment target at 13 weeks. A significant proportion of nonresponders who were at high risk achieved the treatment target with treatment intensification vs continuation (80% vs 44%; difference 36%; P = .04), but experienced more adverse events (P < .01).

Study details: This study included 190 patients with early RA from the COBRA treat-to-target trial, of which high-risk patients received prednisolone (30 mg/day tapered to 7.5 mg/day) and methotrexate (increased from 10 to 25 mg/week). At 13 weeks, nonresponders were randomly assigned to treatment continuation or intensification (methotrexate 25 mg/week; prednisolone 60 mg/day tapered to 7.5 mg/day; sulfasalazine 2 g/day; and hydroxychloroquine 400 mg/day).

Disclosures: This study was supported by an unrestricted grant from Pfizer. M Boers and WF Lems reported ties with various sources.

Source: Hartman L et al. Favorable effect of a ‘second hit’ after 13 weeks in early RA non-responders: The Amsterdam COBRA treat-to-target randomized trial. Rheumatology (Oxford). 2022 (Oct 7). Doi: 10.1093/rheumatology/keac582

Key clinical point: Significant proportion of patients with high-risk early rheumatoid arthritis (RA) achieved the treatment target with a combination of methotrexate and step-down prednisolone, whereas nonresponders benefited from treatment intensification albeit with more adverse events.

Major finding: Overall, 73% of patients at high risk achieved the treatment target at 13 weeks. A significant proportion of nonresponders who were at high risk achieved the treatment target with treatment intensification vs continuation (80% vs 44%; difference 36%; P = .04), but experienced more adverse events (P < .01).

Study details: This study included 190 patients with early RA from the COBRA treat-to-target trial, of which high-risk patients received prednisolone (30 mg/day tapered to 7.5 mg/day) and methotrexate (increased from 10 to 25 mg/week). At 13 weeks, nonresponders were randomly assigned to treatment continuation or intensification (methotrexate 25 mg/week; prednisolone 60 mg/day tapered to 7.5 mg/day; sulfasalazine 2 g/day; and hydroxychloroquine 400 mg/day).

Disclosures: This study was supported by an unrestricted grant from Pfizer. M Boers and WF Lems reported ties with various sources.

Source: Hartman L et al. Favorable effect of a ‘second hit’ after 13 weeks in early RA non-responders: The Amsterdam COBRA treat-to-target randomized trial. Rheumatology (Oxford). 2022 (Oct 7). Doi: 10.1093/rheumatology/keac582

Key clinical point: In patients with psoriatic arthritis (PsA), the percentages of some T_reg cell subgroups and the levels of T_reg-related cytokines, such as transforming growth factor-beta (TGFβ), were decreased.

Major finding: Compared with control individuals without PsA, patients with PsA had a similar proportion of T_reg cells (P = .071), with no significant difference in the proportion of OKT8⁺ T_reg cells (P = .679) and significantly decreased CD4⁺ T_reg cells (standardized mean difference [SMD] −1.501; P = .023). TGFβ levels were lower in patients with PsA vs healthy controls (SMD −2.199; P = .003).

Study details: Findings are from a meta-analysis of 12 studies including 525 patients with PsA and 414 control individuals.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflict of interests.

Source: Su QY et al. Peripheral T_reg levels and transforming growth factor-β (TGFβ) in patients with psoriatic arthritis: A systematic review meta-analysis. Adv Ther. 2022 (Oct 26). Doi: 10.1007/s12325-022-02337-5

Key clinical point: In patients with psoriatic arthritis (PsA), the percentages of some T_reg cell subgroups and the levels of T_reg-related cytokines, such as transforming growth factor-beta (TGFβ), were decreased.

Major finding: Compared with control individuals without PsA, patients with PsA had a similar proportion of T_reg cells (P = .071), with no significant difference in the proportion of OKT8⁺ T_reg cells (P = .679) and significantly decreased CD4⁺ T_reg cells (standardized mean difference [SMD] −1.501; P = .023). TGFβ levels were lower in patients with PsA vs healthy controls (SMD −2.199; P = .003).

Study details: Findings are from a meta-analysis of 12 studies including 525 patients with PsA and 414 control individuals.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflict of interests.

Source: Su QY et al. Peripheral T_reg levels and transforming growth factor-β (TGFβ) in patients with psoriatic arthritis: A systematic review meta-analysis. Adv Ther. 2022 (Oct 26). Doi: 10.1007/s12325-022-02337-5

Key clinical point: In patients with psoriatic arthritis (PsA), the percentages of some T_reg cell subgroups and the levels of T_reg-related cytokines, such as transforming growth factor-beta (TGFβ), were decreased.

Major finding: Compared with control individuals without PsA, patients with PsA had a similar proportion of T_reg cells (P = .071), with no significant difference in the proportion of OKT8⁺ T_reg cells (P = .679) and significantly decreased CD4⁺ T_reg cells (standardized mean difference [SMD] −1.501; P = .023). TGFβ levels were lower in patients with PsA vs healthy controls (SMD −2.199; P = .003).

Study details: Findings are from a meta-analysis of 12 studies including 525 patients with PsA and 414 control individuals.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflict of interests.

Source: Su QY et al. Peripheral T_reg levels and transforming growth factor-β (TGFβ) in patients with psoriatic arthritis: A systematic review meta-analysis. Adv Ther. 2022 (Oct 26). Doi: 10.1007/s12325-022-02337-5

Key clinical point: Serum calprotectin (CLP) serves as an important inflammatory biomarker for diagnosing and monitoring disease activity in psoriatic arthritis (PsA).

Major finding: Participants with PsA vs control individuals without psoriasis or PsA had higher median CLP levels (3.816 vs 0.707 μg/mL; P < .001). The concentration of serum CLP decreased significantly along with the disease activity from 3.816 at baseline to 2.052, 1.681, and 1.655 μg/mL at 3, 6, and 12 months, respectively (all P < .001).

Study details: Findings are from a longitudinal study including 71 patients with PsA, 55 patients with psoriasis, and 50 control individuals.

Disclosures: This study was supported by the interdisciplinary clinical research project of Peking University First Hospital, China, and other sources. The authors declared no conflict of interests.

Source: Li B et al. Serum calprotectin as a promising inflammatory biomarker in psoriatic arthritis: A 1-year longitudinal study. Rheumatol Ther. 2022 (Oct 21). Doi: 10.1007/s40744-022-00501-5

Key clinical point: Serum calprotectin (CLP) serves as an important inflammatory biomarker for diagnosing and monitoring disease activity in psoriatic arthritis (PsA).

Major finding: Participants with PsA vs control individuals without psoriasis or PsA had higher median CLP levels (3.816 vs 0.707 μg/mL; P < .001). The concentration of serum CLP decreased significantly along with the disease activity from 3.816 at baseline to 2.052, 1.681, and 1.655 μg/mL at 3, 6, and 12 months, respectively (all P < .001).

Study details: Findings are from a longitudinal study including 71 patients with PsA, 55 patients with psoriasis, and 50 control individuals.

Disclosures: This study was supported by the interdisciplinary clinical research project of Peking University First Hospital, China, and other sources. The authors declared no conflict of interests.

Source: Li B et al. Serum calprotectin as a promising inflammatory biomarker in psoriatic arthritis: A 1-year longitudinal study. Rheumatol Ther. 2022 (Oct 21). Doi: 10.1007/s40744-022-00501-5

Key clinical point: Serum calprotectin (CLP) serves as an important inflammatory biomarker for diagnosing and monitoring disease activity in psoriatic arthritis (PsA).

Major finding: Participants with PsA vs control individuals without psoriasis or PsA had higher median CLP levels (3.816 vs 0.707 μg/mL; P < .001). The concentration of serum CLP decreased significantly along with the disease activity from 3.816 at baseline to 2.052, 1.681, and 1.655 μg/mL at 3, 6, and 12 months, respectively (all P < .001).

Study details: Findings are from a longitudinal study including 71 patients with PsA, 55 patients with psoriasis, and 50 control individuals.

Disclosures: This study was supported by the interdisciplinary clinical research project of Peking University First Hospital, China, and other sources. The authors declared no conflict of interests.

Source: Li B et al. Serum calprotectin as a promising inflammatory biomarker in psoriatic arthritis: A 1-year longitudinal study. Rheumatol Ther. 2022 (Oct 21). Doi: 10.1007/s40744-022-00501-5

Key clinical point: The Disease Activity index for Psoriatic Arthritis (DAPSA) based on a quick quantitative C-reactive protein (qCRP) assay (Q-DAPSA) showed perfect agreement with conventional DAPSA in the majority of patients with PsA.

Major finding: Overall, 98.1% of patients were similarly categorized into disease activity groups (remission and low, moderate, and high disease activity) using Q-DAPSA and DAPSA, with both indices showing identical numerical values in 57.7% of patients.

Study details: Findings are from a multicenter, cross-sectional study including 104 patients with PsA and available CRP values (measured by routine laboratory and quick qCRP assays).

Disclosures: This study was partially supported by Novartis. The authors declared receiving grants, personal fees, or support for attending meetings and travels from Novartis and other sources.

Source: Proft F et al. Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: A prospective multicentre cross-sectional study. RMD Open. 2022;8:e002626 (Nov 2). Doi: 10.1136/rmdopen-2022-002626

Key clinical point: The Disease Activity index for Psoriatic Arthritis (DAPSA) based on a quick quantitative C-reactive protein (qCRP) assay (Q-DAPSA) showed perfect agreement with conventional DAPSA in the majority of patients with PsA.

Major finding: Overall, 98.1% of patients were similarly categorized into disease activity groups (remission and low, moderate, and high disease activity) using Q-DAPSA and DAPSA, with both indices showing identical numerical values in 57.7% of patients.

Study details: Findings are from a multicenter, cross-sectional study including 104 patients with PsA and available CRP values (measured by routine laboratory and quick qCRP assays).

Disclosures: This study was partially supported by Novartis. The authors declared receiving grants, personal fees, or support for attending meetings and travels from Novartis and other sources.

Source: Proft F et al. Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: A prospective multicentre cross-sectional study. RMD Open. 2022;8:e002626 (Nov 2). Doi: 10.1136/rmdopen-2022-002626

Key clinical point: The Disease Activity index for Psoriatic Arthritis (DAPSA) based on a quick quantitative C-reactive protein (qCRP) assay (Q-DAPSA) showed perfect agreement with conventional DAPSA in the majority of patients with PsA.

Major finding: Overall, 98.1% of patients were similarly categorized into disease activity groups (remission and low, moderate, and high disease activity) using Q-DAPSA and DAPSA, with both indices showing identical numerical values in 57.7% of patients.

Study details: Findings are from a multicenter, cross-sectional study including 104 patients with PsA and available CRP values (measured by routine laboratory and quick qCRP assays).

Disclosures: This study was partially supported by Novartis. The authors declared receiving grants, personal fees, or support for attending meetings and travels from Novartis and other sources.

Source: Proft F et al. Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: A prospective multicentre cross-sectional study. RMD Open. 2022;8:e002626 (Nov 2). Doi: 10.1136/rmdopen-2022-002626

Key clinical point: The addition of ultrasound-detected features, such as tenosynovitis and enthesitis, to the CASPAR (ClASsification criteria for Psoriatic Arthritis) scoring system improved its diagnostic utility.

Major finding: Specificity improved (84.0% to 91.4%) and sensitivity was similar (94.5% to 95.7%) after ultrasound features, such as tenosynovitis and enthesitis, were integrated in the original CASPAR criteria which had been based on physical examination.

Study details: Findings are from a cross-sectional study including 326 participants, of which 164 were diagnosed with PsA.

Disclosures: This study was supported by the Interdisciplinary Clinical Research Project of the Peking University First Hospital, China, and other sources. The authors declared no conflict of interests.

Source: Geng Y et al. Improved diagnostic performance of CASPAR criteria with integration of ultrasound. Front Immunol. 2022;13:935132 (Oct 10). Doi: 10.3389/fimmu.2022.935132

Key clinical point: The addition of ultrasound-detected features, such as tenosynovitis and enthesitis, to the CASPAR (ClASsification criteria for Psoriatic Arthritis) scoring system improved its diagnostic utility.

Major finding: Specificity improved (84.0% to 91.4%) and sensitivity was similar (94.5% to 95.7%) after ultrasound features, such as tenosynovitis and enthesitis, were integrated in the original CASPAR criteria which had been based on physical examination.

Study details: Findings are from a cross-sectional study including 326 participants, of which 164 were diagnosed with PsA.

Disclosures: This study was supported by the Interdisciplinary Clinical Research Project of the Peking University First Hospital, China, and other sources. The authors declared no conflict of interests.

Source: Geng Y et al. Improved diagnostic performance of CASPAR criteria with integration of ultrasound. Front Immunol. 2022;13:935132 (Oct 10). Doi: 10.3389/fimmu.2022.935132

Key clinical point: The addition of ultrasound-detected features, such as tenosynovitis and enthesitis, to the CASPAR (ClASsification criteria for Psoriatic Arthritis) scoring system improved its diagnostic utility.

Major finding: Specificity improved (84.0% to 91.4%) and sensitivity was similar (94.5% to 95.7%) after ultrasound features, such as tenosynovitis and enthesitis, were integrated in the original CASPAR criteria which had been based on physical examination.

Study details: Findings are from a cross-sectional study including 326 participants, of which 164 were diagnosed with PsA.

Disclosures: This study was supported by the Interdisciplinary Clinical Research Project of the Peking University First Hospital, China, and other sources. The authors declared no conflict of interests.

Source: Geng Y et al. Improved diagnostic performance of CASPAR criteria with integration of ultrasound. Front Immunol. 2022;13:935132 (Oct 10). Doi: 10.3389/fimmu.2022.935132

Key clinical point: Patients with psoriatic arthritis (PsA) were more likely to have cardiovascular diseases (CVD) and metabolic syndrome (MS) than patients with rheumatoid arthritis (RA).

Major finding: MS (odds ratio [OR] 1.54; P = .002) and CVD (OR 6.13; P = .001) were more frequently observed in patients with PsA vs RA.

Study details: Findings are from a cross-sectional study including 197 patients with PsA and 279 patients with RA.

Disclosures: This study was supported by Peking University First Hospital, China, and other sources. The authors declared no conflict of interests.

Source: Li B et al. Discrepancy in metabolic syndrome between psoriatic arthritis and rheumatoid arthritis: A direct comparison of two cohorts in one center. Rheumatol Ther. 2022 (Oct 20). Doi: 10.1007/s40744-022-00502-4

Key clinical point: Patients with psoriatic arthritis (PsA) were more likely to have cardiovascular diseases (CVD) and metabolic syndrome (MS) than patients with rheumatoid arthritis (RA).

Major finding: MS (odds ratio [OR] 1.54; P = .002) and CVD (OR 6.13; P = .001) were more frequently observed in patients with PsA vs RA.

Study details: Findings are from a cross-sectional study including 197 patients with PsA and 279 patients with RA.

Disclosures: This study was supported by Peking University First Hospital, China, and other sources. The authors declared no conflict of interests.

Source: Li B et al. Discrepancy in metabolic syndrome between psoriatic arthritis and rheumatoid arthritis: A direct comparison of two cohorts in one center. Rheumatol Ther. 2022 (Oct 20). Doi: 10.1007/s40744-022-00502-4

Key clinical point: Patients with psoriatic arthritis (PsA) were more likely to have cardiovascular diseases (CVD) and metabolic syndrome (MS) than patients with rheumatoid arthritis (RA).

Major finding: MS (odds ratio [OR] 1.54; P = .002) and CVD (OR 6.13; P = .001) were more frequently observed in patients with PsA vs RA.

Study details: Findings are from a cross-sectional study including 197 patients with PsA and 279 patients with RA.

Disclosures: This study was supported by Peking University First Hospital, China, and other sources. The authors declared no conflict of interests.

Source: Li B et al. Discrepancy in metabolic syndrome between psoriatic arthritis and rheumatoid arthritis: A direct comparison of two cohorts in one center. Rheumatol Ther. 2022 (Oct 20). Doi: 10.1007/s40744-022-00502-4

Key clinical point: Among patients with psoriatic arthritis (PsA), sonographic enthesitis was more prevalent in men than women.

Major finding: Compared with women, men had higher total ultrasound and gray scale enthesitis scores (both P = .01) and sonographic active inflammatory score (P = .005), as reflected by higher hypoechogenicity, thickening, and enthesophytes (P < .05), with the male sex being associated with a significantly higher ultrasound inflammatory enthesitis score (P = .02).

Study details: Findings are from a prospective study including 158 patients with PsA, of which 70 patients were men and 88 were women.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Furer V et al. Sex-based differences in sonographic and clinical findings among patients with psoriatic arthritis. J Rheumatol. 2022 (Oct 15). Doi: 10.3899/jrheum.220547

Key clinical point: Among patients with psoriatic arthritis (PsA), sonographic enthesitis was more prevalent in men than women.

Major finding: Compared with women, men had higher total ultrasound and gray scale enthesitis scores (both P = .01) and sonographic active inflammatory score (P = .005), as reflected by higher hypoechogenicity, thickening, and enthesophytes (P < .05), with the male sex being associated with a significantly higher ultrasound inflammatory enthesitis score (P = .02).

Study details: Findings are from a prospective study including 158 patients with PsA, of which 70 patients were men and 88 were women.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Furer V et al. Sex-based differences in sonographic and clinical findings among patients with psoriatic arthritis. J Rheumatol. 2022 (Oct 15). Doi: 10.3899/jrheum.220547

Key clinical point: Among patients with psoriatic arthritis (PsA), sonographic enthesitis was more prevalent in men than women.

Major finding: Compared with women, men had higher total ultrasound and gray scale enthesitis scores (both P = .01) and sonographic active inflammatory score (P = .005), as reflected by higher hypoechogenicity, thickening, and enthesophytes (P < .05), with the male sex being associated with a significantly higher ultrasound inflammatory enthesitis score (P = .02).

Study details: Findings are from a prospective study including 158 patients with PsA, of which 70 patients were men and 88 were women.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Furer V et al. Sex-based differences in sonographic and clinical findings among patients with psoriatic arthritis. J Rheumatol. 2022 (Oct 15). Doi: 10.3899/jrheum.220547

Key clinical point: Patients with psoriatic arthritis (PsA) experienced a slowing of radiographic progression during treatment with etanercept.

Major finding: In patients with available pre-etanercept radiographic data, the annualized radiographic progression was significantly lower with etanercept during the first 18 months than during the pre-etanercept treatment period (P < .005), and a higher proportion of patients showed no progression during etanercept treatment (61.7%) than during the pre-etanercept period (55.3%).

Study details: Findings are from a real-world, noninterventional study including 1821 participants who started treatment with etanercept, of which 1378 patients had rheumatoid arthritis and 440 patients had PsA.

Disclosures: This study was funded by Pfizer. Five authors declared being current or former employees of Pfizer, and the other authors reported ties with several sources, including Pfizer.

Source: Wassenberg S et al. Etanercept is effective and halts radiographic progression in rheumatoid arthritis and psoriatic arthritis: Final results from a German non-interventional study (PRERA). Rheumatol Ther. 2022 (Oct 17). Doi: 10.1007/s40744-022-00491-4

Key clinical point: Patients with psoriatic arthritis (PsA) experienced a slowing of radiographic progression during treatment with etanercept.

Major finding: In patients with available pre-etanercept radiographic data, the annualized radiographic progression was significantly lower with etanercept during the first 18 months than during the pre-etanercept treatment period (P < .005), and a higher proportion of patients showed no progression during etanercept treatment (61.7%) than during the pre-etanercept period (55.3%).

Study details: Findings are from a real-world, noninterventional study including 1821 participants who started treatment with etanercept, of which 1378 patients had rheumatoid arthritis and 440 patients had PsA.

Disclosures: This study was funded by Pfizer. Five authors declared being current or former employees of Pfizer, and the other authors reported ties with several sources, including Pfizer.

Source: Wassenberg S et al. Etanercept is effective and halts radiographic progression in rheumatoid arthritis and psoriatic arthritis: Final results from a German non-interventional study (PRERA). Rheumatol Ther. 2022 (Oct 17). Doi: 10.1007/s40744-022-00491-4

Key clinical point: Patients with psoriatic arthritis (PsA) experienced a slowing of radiographic progression during treatment with etanercept.

Major finding: In patients with available pre-etanercept radiographic data, the annualized radiographic progression was significantly lower with etanercept during the first 18 months than during the pre-etanercept treatment period (P < .005), and a higher proportion of patients showed no progression during etanercept treatment (61.7%) than during the pre-etanercept period (55.3%).

Study details: Findings are from a real-world, noninterventional study including 1821 participants who started treatment with etanercept, of which 1378 patients had rheumatoid arthritis and 440 patients had PsA.

Disclosures: This study was funded by Pfizer. Five authors declared being current or former employees of Pfizer, and the other authors reported ties with several sources, including Pfizer.

Source: Wassenberg S et al. Etanercept is effective and halts radiographic progression in rheumatoid arthritis and psoriatic arthritis: Final results from a German non-interventional study (PRERA). Rheumatol Ther. 2022 (Oct 17). Doi: 10.1007/s40744-022-00491-4